The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I CITN-12: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm. Cancer Immunotherapy Trials Network; Uldrick, Thomas S. (301) 402-6296... […]
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A multicomponent outreach program increased completion of the three-dose human papillomavirus vaccination series that reduces the risk of cervical cancer, according to a joint study by UT Southwestern Medical Center and Parkland Health & Hospital System.
Telotristat etiprate showed clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study.
Lenvatinib, used in combination with everolimus, demonstrated significantly improved progression-free survival compared everolimus alone in people with metastatic renal cell carcinoma following prior VEGF-targeted therapy in a phase II trial.
A phase II clinical study of the WT1 cancer vaccine, developed by SELLAS Life Sciences Group, showed increased median overall survival in patients with malignant pleural mesothelioma.
Hypofractionated radiation therapy, which is delivered in larger doses over a shorter time period than conventional RT, can result in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research presented at the American Society for Radiation Oncology's annual meeting.
Patients with locally advanced non-small cell lung cancer that received intensity modulated radiation therapy had less severe lung toxicity and were able to better tolerate their chemotherapy compared to patients who received 3D conformal radiation therapy, according to a secondary analysis of a large phase III trial.
A prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation with interstitial multicatheter brachytherapy to whole breast irradiation showed that APBI brachytherapy lead to equivalent overall survival and local and regional cancer control rates, as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers.
FDA approved Imlygic (talimogene laherparepvec) as the first oncolytic viral therapy in the U.S.
